a), c), b). The actual numbers are 10%, 7%, and 6%.
SVR rate (choice a) ) trumps everything in treating HCV, according to the surveyed physicians.
Choice c) – expansion of the Albuferon treatment interval to one month – did not score as high as some people expected because doctors who thought the dosing interval was very important generally responded to the survey with a high “base case” market share for Albuferon, leaving less upside for incremental market share from monthly rather than biweekly dosing.
The 6% and 7% figures for b) and c) are close enough to be essentially equal for statistical purposes, so either “acb” or “abc” are correct answers to the quiz. The main take-away is that the SVR rate trumps all other considerations.
Market Data 
Markets 
AI
